Five-year experience with infliximab: Follow up of the product familiarisation program.

Nguyen, Rebecca; Braue, Anna; Baker, Chris; Foley, Peter

Nguyen, Rebecca; Braue, Anna; Baker, Chris; Foley, Peter.

Affiliation

Nguyen R; Skin and Cancer Foundation, Melbourne, Victoria, Australia.
Braue A; Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Baker C; Skin and Cancer Foundation, Melbourne, Victoria, Australia.
Foley P; Skin and Cancer Foundation, Melbourne, Victoria, Australia.

Australas J Dermatol ; 57(4): 300-306, 2016 Nov.

Article in En | MEDLINE | ID: mdl-26374405

Subject(s)

Dermatologic Agents/therapeutic use; Infliximab/therapeutic use; Psoriasis/drug therapy; Adult; Aged; Dermatologic Agents/adverse effects; Drug Resistance; Female; Follow-Up Studies; Humans; Infliximab/adverse effects; Male; Middle Aged; Quality of Life; Retrospective Studies; Severity of Illness Index

Key words

DLQI; PASI; adverse event; biologic; infection; infliximab; psoriasis; skin cancer

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents / Infliximab Type of study: Guideline / Observational_studies / Prognostic_studies Language: En Journal: Australas J Dermatol Year: 2016 Type: Article Affiliation country: Australia

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google